Cell line · CVCL_0302
Papers87
1 to 20 of 87
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| PubMed 42996501 | Acta Pharm Sin B | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Quercetin Attenuates Cisplatin-Induced Nephrotoxicity While Enhancing Antitumor Efficacy in Gastric Cancer via Cell Type-Specific Modulation of the ERK1/2 Pathway. | J Biochem Mol Toxicol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TH1177, Clemastine, and Benzhydryl Derivatives Act as Novel Extracellular Blockers of ORAI Channels. | Biomolecules | 2026 | Its Methods give the RRID and name the line | PubMed | |
| S100A1 Promotes MDM2-Mediated KLF15 Ubiquitination to Regulate ID1-Driven Tubular Injury in Diabetic Kidney Disease. | FASEB J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Gut Microbiota-Isoallolithocholic Acid Crosstalk Promotes Calcium Oxalate Kidney Stone Formation via PARP1-Mediated Parthanatos. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Naja atra SVPLA2 contributes to venom-induced AKI via HRAS palmitoylation-dependent PI3K-AKT inactivation. | J Lipid Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Hirudin Attenuates Uric Acid-Induced Renal Tubular Injury via TNFRSF6B-Mediated Suppression of NF-κB Signaling. | Pharmacol Res Perspect | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Diagnostic potential of B-cell translocation gene 2 in IgA nephropathy: Insights from molecular mechanisms. | J Cell Commun Signal | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CROP2, a Retriever-PROPPIN complex mediating protein export from endosomes to the plasma membrane in human cells. | Elife | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Tubular tRF‑1:30‑Gln‑CTG‑4 attenuates tubulointerstitial fibrosis by mitigating FBXO7-mediated mitophagy defect in diabetic kidney disease. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Bio-hybrid nanovesicles with multimodal antioxidant and immunomodulatory functions attenuate acute kidney injury. | J Nanobiotechnology | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Transcriptomics reveal dysregulated genes during folic acid-induced acute injury and fibrosis in kidney and their attenuation by antioxidant N-acetyl cysteine. | Am J Physiol Cell Physiol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Qingxin Lianzi Yin Improves Chronic Kidney Disease by Targeting Ferroptosis via the TLR4/HIF-1α Pathway. | Mediators Inflamm | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A kidney-protective mechanism via cellular oxidative stress reduction induced by CD5L protein. | Cell Death Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cross-Cohort Transcriptomic Integration Identifies IFIT2 as a Translational Diagnostic Biomarker and Functional Driver of Inflammation-Linked Tubular Injury in Chronic Kidney Disease. | Hum Mutat | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Integrating Bulk and Single-Cell RNA-Seq Reveals Glycolysis-Associated Macrophages and Its Related Tumor Subgroup Signatures to Predict Prognosis and Therapy in Clear Cell Renal Cell Carcinoma. | Hum Mutat | 2026 | Its Methods give the RRID and name the line | PubMed | |
| USP18 promotes clear cell renal cell carcinoma progression by regulating the ubiquitination and stability of YBX3. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Enhancing platinum-based chemotherapy efficacy and safety through combination therapy-mediated remodeling of autophagic homeostasis in gastric cancer. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Ultrasmall Au10-12 Nanoclusters: A Novel Platform for 223Ra-Targeted Tumor α-Therapy. | Exploration (Beijing) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| VHL-recruiting PROTAC attenuates AKI-CKD transition via simultaneous degradation of Smad3 and stabilization of HIF-2α. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0302/papers